COMPANY PROFILE

BioImagene

Explore full profile

Tissue-based integrated hardware and software solutions for clinical diagnostics and drug discovery applications

Sunnyvale, United StatesFounded 2003Biotech & Life Sciences

Valuation $100–250M Last recorded · 2010

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About BioImagene

BioImagene operates in the biotechnology sector, specializing in hybridoma technology for DNA modification and GMO research. The company serves clients in the scientific research and agricultural industries, providing advanced technological applications that utilize biological systems and living organisms to create or modify products and processes. BioImagene's business model revolves around offering cutting-edge biotechnological solutions that cater to the needs of researchers and agricultural professionals. Revenue is generated through the sale of proprietary technology, consulting services, and research collaborations.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2003
Headquarters: Sunnyvale, United States
Employees: 37
Open positions: None listed
Dealroom signal: 66.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
Technology: Hardware
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Aug 2010	$100M	$100M	Undisclosed	—
SERIES D✓Equity / VC	Aug 2008	$26M	$104M	Artiman Ventures · Ascension · Burrill · National Healthcare Services	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

BioImagene website traffic

Latest recorded traffic for BioImagene is 20 monthly website visits, down 91.3% over the last three months. BioImagene's team declined 27.5% over the past year.

Latest monthly visits20 3-month web change-91.3% 1-year team growth-27.5%

Monthly website visitsOct 2017–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBioMindBioMind is developed in collaboration with the world's largest hospital for neurological diseases	Singapore, Singapore	Operational	29	—	—
FBFK BiotecnologiaFK Biotecnologia SA manufactures biotech-based products	Porto Alegre, Brazil	Operational
MTMedicenna TherapeuticsClinical stage, privately held, immuno-oncology company	Vancouver, Canada	Operational
CTCARsgen TherapeuticsA leading immunotherapy company focused on the development of new chimeric antigen receptor	Xuhui District, China	Operational
STSapience TherapeuticsA preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs	Town of Greenburgh, United States	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational
RIRigontecRNA-based immunotherapeutics for the treatment of cancer and viral diseases	Bonn, Germany	Acquired
APApogenixApogenix - protein therapeutics for the treatment of cancer	Heidelberg, Germany	Operational